Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coli | Zendy

N. Lampri | Zendy; Irene Galani | Zendy; Garyphallia Poulakou | Zendy; Ioannis Katsarolis | Zendy; G. Petrikkos | Zendy; Helen Giamarellou | Zendy; Maria Souli | Zendy

Open Access

Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coli

Author(s) -

N. Lampri,

Irene Galani,

Garyphallia Poulakou,

Ioannis Katsarolis,

G. Petrikkos,

Helen Giamarellou,

Maria Souli

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks215

Subject(s) - mecillinam , microbiology and biotechnology , escherichia coli , agar dilution , agar dilution method , biology , agar , enterobacteriaceae , bacteria , antimicrobial , minimum inhibitory concentration , biochemistry , genetics , gene

Extended-spectrum β-lactamases (ESBLs) have emerged as an important mechanism of β-lactam resistance among community uropathogens. We characterized the ESBLs of a collection of Escherichia coli isolates recovered from outpatients with urinary tract infection during nationwide surveillance conducted from 2005 to 2006 in Greece, and evaluated the in vitro activity of mecillinam and mecillinam/clavulanate against them.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research